ARMC
DFTX

American Research & Management Company’s Definium Therapeutics DFTX Stock Holding History

American Research & Management Company’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-67
Closed -$1K – 439
2022
Q2 		$1K Hold
67
– – ﹤0.01% 384
2022
Q1 		$1K Hold
67
– – ﹤0.01% 388
2021
Q4 		$1K Hold
67
– – ﹤0.01% 378
2021
Q3 		$2K Hold
67
– – ﹤0.01% 357
2021
Q2 		$3K Buy
+67
New +$3.52K ﹤0.01% 356

Other funds holding DFTX

DCI
Data Collective IV Palo Alto, California $78.6M AUM 55.41% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $4.12B AUM 32.66% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

American Research & Management Company's DFTX Position: Q3 2022 in Review

American Research & Management Company sold out of Definium Therapeutics (DFTX) in Q3 2022, closing a stake of 67 shares — an estimated $1K sold.

American Research & Management Company first reported a position in DFTX in Q2 2021 and held it in 5 quarters. The position peaked at $3K in Q2 2021. 101 funds tracked by Wall St. Rank hold DFTX as of Q3 2022.

  • American Research & Management Company reported no remaining Definium Therapeutics position as of Q3 2022 after selling out during the quarter.
  • American Research & Management Company sold 67 Definium Therapeutics shares in Q3 2022, an estimated $1K.
  • American Research & Management Company first reported a position in Definium Therapeutics in Q2 2021 and held it in 5 quarters.
  • American Research & Management Company's Definium Therapeutics position peaked at $3K in Q2 2021.
  • 101 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2022.

Based on American Research & Management Company's 13F filing for Q3 2022, filed 7 Oct 2022.